SAMSUNG-ELECTRONICS
12.1.2021 16:07:33 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced the Exynos 2100 through its first virtual event, Exynos On 2021 (www.youtube.com/samsung ). The new mobile processor is the company’s first premium 5G-integrated mobile processor built on the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005748/en/
“Our Exynos team has been committed to creating premium mobile computing experiences by bringing innovations to processors that are at the heart of today’s smart devices,” said Inyup Kang, president of System LSI Business at Samsung Electronics. “Today we are delighted to introduce the Exynos 2100, our most advanced mobile processor yet. Armed with powerful processing technologies and an advanced 5G modem on a power-efficient 5nm process node, Exynos 2100 will set a new standard for tomorrow’s flagship mobile devices.”
“At Samsung Electronics, we are dedicated to providing innovative technologies and services with our flagship devices to deliver the ultimate mobile experience to our customers,” said Kyeongjun Kim, Executive Vice President and head of Mobile R&D Office at Mobile Communications Business, Samsung Electronics. “With powerful processing, fast 5G connectivity, and intelligent AI-acceleration, the Exynos 2100 offers the utmost performance that meets the stringent quality standards and requirements for our next generation smartphone.”
“The evolution of technologies such as 5G, advanced graphics and machine learning have been critical in enabling new mobile experiences,” said Paul Williamson, vice president and general manager, Client Line of Business at Arm. “Arm and Samsung have collaborated closely to incorporate Arm’s powerful next-generation compute and graphics platform, at the heart of the Samsung Exynos 2100. As a result of our partnership, we are able to maximize performance and make these experiences a reality in next-generation mobile devices while delivering exceptional battery life.”
The chip’s computation and graphic processing performance have been improved and refined to surpass the power user’s performance expectations. As Samsung’s first 5G-integrated flagship mobile processor, the Exynos 2100 is built on an advanced 5nm EUV process technology that allows up to 20-percent lower power consumption or 10-percent higher overall performance than the 7nm predecessor. For further enhancement, the chip offers improved cache memory utilization and a stronger scheduler. The octa-core CPU comes in an improved tri-cluster structure made up of a single powerful Arm® Cortex® -X1 core that runs at up to 2.9GHz, three high-performing Cortex-A78 cores and four power-efficient Cortex-A55 cores delivering more than 30-percent enhancement in multi-core performance than the predecessor.
The Arm Mali™ -G78, which supports the latest APIs such as Vulkan and OpenCL, improves graphic performance by more than 40-percent for visually stunning and seamless graphics, enabling the most immersive on-screen mobile experiences yet, including gaming and AR/VR or MR(Mixed Reality). The Exynos 2100 also integrates advanced multi-IP governor (AMIGO) technology, which overlooks and optimizes power usages of CPU, GPU, and other processes, allowing longer use time even with intense on-screen activities. With such comprehensive efforts to increase energy efficiency of its products across software and hardware technologies, Samsung also continues its strive to help minimize the carbon footprint of tomorrow’s mobile devices.
AI capabilities will also enjoy a significant boost with the Exynos 2100. The newly-designed tri-core NPU has architectural enhancements such as minimizing unnecessary operations for high effective utilization and support for feature-map and weight compression. Exynos 2100 can perform up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation. With on-device AI processing and support for advanced neural networks, users will be able to enjoy more interactive and smart features as well as enhanced computer vision performance in applications such as imaging.
The Exynos 2100’s advanced image signal processor (ISP) supports camera resolutions of up to 200-megapixels (Mp). It can connect up to six individual sensors and is able to process four concurrently for richer multi-camera experiences. With a multi-camera and frame processor (MCFP), the ISP can combine feeds from multiple cameras to improve zoom performance, enhance image quality for ultra-wide shots and more. With AI acceleration, the ISP offers a content-aware feature that quickly and seamlessly recognizes scenes, faces and objects and optimally adjusts the camera settings to capture the image with fuller detail.
The Exynos 2100’s integrated 5G modem supports 5G’s sub-6GHz and mmWave spectrums from 2G GSM/CDMA, 3G WCDMA and 4G LTE, for strong network coverage and reliability. The modem delivers a maximum downlink speed of up to 5.1-gigabits per second (Gbps) in sub-6-gigahertz (GHz) and 7.35Gbps in mmWave, or up to 3.0Gbps in 4G networks with 1024 Quadrature Amplitude Modulation (QAM) support.
The Exynos 2100 is currently in mass production.
For more information about Samsung’s Exynos products, please visit http://www.samsung.com/exynos .
Process |
5nm |
AI |
26 TOPS |
Multi-core |
Octa-core |
CPU (Main) |
Arm Cortex-X1 (2.9GHz) |
CPU (Sub) |
Arm Cortex-A78 and Cortex-A55 |
GPU |
Arm Mali-G78 |
Connectivity |
5G (sub-6GHz/mmWave), 4G LTE (1024 QAM), 3G WCDMA, 2G GSM/CDMA |
Memory |
LPDDR5 (51.2GB/s) |
Storage |
UFS 3.1, UFS 2.1 |
Camera (Rear) |
200MP |
Video (Encoding) |
4K UHD 120fps |
Video (Decoding) |
8K 60fps |
# # #
* Editor's Note: Actual performance may vary depending on device and user environment.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005748/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom